Position in ANVS
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$4,466,745
New position
Shares Held
2,401,476
first reported quarter
Ownership
5.64%
of shares outstanding
% of Portfolio
5.24%
of 13F equity value
Holder Rank
#1
of 61 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Empery Asset Management, LP holds $59,327,152 across 12 Biotechnology names. ANVS ranks #4 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | XFOR |
X4 Pharmaceuticals, Inc
|
6,930,591 | $32,365,859 | |
| 2 | NGEN |
Nervgen Pharma Corp.
|
4,000,000 | $8,240,000 | |
| 3 | DTIL |
Precision Biosciences Inc
|
776,093 | $6,100,090 | |
| 4 | ANVS |
Annovis Bio, Inc.
This page
|
2,401,476 | $4,466,745 | |
| 5 | LTRN |
Lantern Pharma Inc.
|
842,669 | $3,513,929 | |
| 6 | TNYA |
Tenaya Therapeutics, Inc.
|
3,863,115 | $2,854,841 | |
| 7 | MSLE |
Satellos Bioscience Inc.
|
107,100 | $832,702 | |
| 8 | CLRB |
Cellectar Biosciences, Inc.
|
189,605 | $527,101 |
All Filings in ANVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,466,745 | 2,401,476 | Shares | Sole | 2026-08-11 | |
| 2026-06-30 | $4,466,745 | 2,401,476 | Shares | Sole | 2026-07-29 | |
| No filing history on record for this holder in this stock. | ||||||